论文部分内容阅读
本文报告经淋巴管内灌注多联抗癌药物治疗晚期或复发转移恶性肿瘤31例,其中恶性淋巴瘤8例,胃癌8例,卵巢癌8例,直肠肛管癌4例,其他癌3例,除1例纵膈恶性淋巴瘤外,全部经病理证实。男性19例,女性12例,年龄从30～67岁,平均年龄48.8岁,每次灌注剂量,胃癌、直肠癌、卵巢癌用甲氨喋啶150mg+5-Fu2000mg+环磷酰胺1200mg;恶性淋巴瘤用环磷酰胺1600mg+甲氨喋啶150mg。治疗结果12例取得完全或部份缓解,总的有效率为38.7％,对恶性淋巴瘤和卵巢癌疗效较好,认为淋巴管内灌注抗癌药物能提高一些肿瘤的切除率和治愈率,化疗反应轻,值得推广应用。
This report reported 31 cases of advanced or recurrent metastasis malignancies treated with lymphatic infusion multi-line anticancer drugs, including 8 cases of malignant lymphoma, 8 cases of gastric cancer, 8 cases of ovarian cancer, 4 cases of rectal anal cancer, and 3 cases of other cancers. One case of mediastinal lymphoma was confirmed by pathology. 19 males and 12 females, aged from 30 to 67 years, mean age 48.8 years, per infusion dose, gastric cancer, rectal cancer, ovarian cancer with methamidodine 150mg + 5-Fu 2000mg + cyclophosphamide 1200mg; malignant lymphoma Cyclophosphamide 1600 mg+metacridine 150 mg was used. The results of treatment were completely or partially relieved in 12 cases. The total effective rate was 38.7%. The curative effect on malignant lymphoma and ovarian cancer was better. It is believed that the infusion of anticancer drugs into the lymphatic vessels can increase the resection rate and cure rate of some tumors. Light, it is worth promoting.